Chairman Of Indian Pharmacopoeia Commission Jun 2026
His leadership focuses on advancing the Indian Pharmacopoeia (IP) —the official book of standards for drugs in India—to meet modern global benchmarks. Why This Leadership Matters Today
To understand the significance of the Chairman, one must first appreciate the mandate of the IPC. Established to perform the functions of the Central Drugs Standard Control Organization (CDSCO) regarding the publication of the Pharmacopoeia, the IPC is the authority that defines the identity, purity, and strength of medicines. The "Indian Pharmacopoeia" (IP), the official book of drug standards published by the commission, is a legal document. Compliance with its standards is mandatory for the manufacture, sale, and distribution of drugs in India. Therefore, the Chairman of the IPC is not just a bureaucratic head but the chief arbiter of pharmaceutical quality in the country.
Promoting the recognition of IP standards globally and harmonizing them with other major pharmacopoeias like the USP, BP, and EP. chairman of indian pharmacopoeia commission
The Chairman heads the highest level of the IPC's three-tier governance structure, providing strategic leadership to ensure the quality, safety, and efficacy of medicines manufactured and sold in India. Governance Structure of the IPC
During the ranitidine (NDMA impurity) scandal, the Chairman’s office was criticized for a delayed response compared to the US FDA. This section analyzes how the Chairman subsequently accelerated the IPC’s adoption of elemental impurities guidelines (ICH Q3D). His leadership focuses on advancing the Indian Pharmacopoeia
The Chairman’s ad-hoc committee published 15 new monographs for antivirals (Favipiravir) and biologics (Vaccine excipients) in record time. This demonstrated a shift from a bureaucratic to a crisis-driven leadership model.
However, the role is not without its challenges. The Chairman must navigate the delicate balance between affordability and quality. In a price-sensitive market like India, there is constant pressure to keep drug costs low. The Chairman must ensure that setting high standards does not become a prohibitive barrier for smaller manufacturers, yet cannot compromise on safety. This requires diplomatic skill and a deep understanding of the pharmaceutical industry’s economics. Additionally, the rise of complex biologicals, biosimilars, and medical devices presents new scientific challenges that require the Chairman to constantly upgrade the technical capabilities of the commission. The "Indian Pharmacopoeia" (IP), the official book of
Also led by the Health Secretary, it manages the executive functions and administrative control of the commission.
is no stranger to the world of drug safety. Before stepping into his current role, he was a key figure in building India's drug monitoring infrastructure.